Cardiovascular Infection Research Group, School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin 2, Ireland; Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin 2, Ireland.
Department of Anaesthesia and Critical Care Medicine, RCSI University of Medicine and Health Sciences, Beaumont Hospital, Dublin, Ireland.
Drug Discov Today. 2020 Dec;25(12):2317-2325. doi: 10.1016/j.drudis.2020.09.038. Epub 2020 Oct 6.
Sepsis is a life-threatening condition caused by the response of the body to an infection, and has recently been regarded as a global health priority because of the lack of effective treatments available. Vascular endothelial cells have a crucial role in sepsis and are believed to be a major target of pathogens during the early stages of infection. Accumulating evidence suggests that common sepsis pathogens, including bacteria, fungi, and viruses, all contain a critical integrin recognition motif, Arg-Gly-Asp (RGD), in their major cell wall-exposed proteins that might act as ligands to crosslink to vascular endothelial cells, triggering systemic dysregulation resulting in sepsis. In this review, we discuss the potential of anti-integrin therapy in the treatment of sepsis and septic shock.
脓毒症是一种危及生命的疾病，由身体对感染的反应引起。由于缺乏有效的治疗方法，脓毒症最近被视为全球卫生重点。血管内皮细胞在脓毒症中起着至关重要的作用，并且被认为是感染早期病原体的主要靶标。越来越多的证据表明，常见的脓毒症病原体，包括细菌、真菌和病毒，在其主要暴露于细胞壁的蛋白质中都含有一个关键的整合素识别基序 Arg-Gly-Asp（RGD），它可能作为配体与血管内皮细胞交联，触发全身性失调导致脓毒症。在这篇综述中，我们讨论了抗整合素治疗在脓毒症和感染性休克治疗中的潜力。
